HGF/c-Met comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
In March 2022, the first "Fridays and Go", a takeaway and quick service version of TGI Fridays, launched in Dundee, Scotland. Despite initial plans to open up to thirty other branches, it remained the sole example until it closed in October 2024 following the sale of the bankrupt UK franchise. In December 2023, SouthRock Capital, the operator of all of the TGI Fridays locations in Brazil, declared bankruptcy, continuing to operate most TGI Fridays locations normally while closing a few underperforming ones, while restructuring through the bankruptcy procedure. SouthRock Capital later declared Chapter 15 bankruptcy in June 2024. On January 4, 2024, TGI Fridays abruptly closed 36 underperforming restaurants and sold eight more to former CEO Ray Blanchette. Most employees were offered transfer to other locations. In April 2024, TGI Fridays entered an agreement to be acquired by Hostmore LLC, the owner of TGI Friday's restaurants in the UK, and for the combined company to go public on the London Stock Exchange. In May 2024 in the US, TGI Friday's entered a licensing agreement with Kraft Heinz to sell TGI Fridays-branded appetizers in supermarkets.
=== Cognition === Vascular health is critical in maintaining cognitive function. IGF-1 plays an essential role in vascular remodelling of the brain and supports cognitive retention. Metabolic IGF-1 levels tend to reduce with age and this reduction appears to be a major contributor to cognitive impairment in older populations. Low or deficient IGF-1 levels can be normalized by cGP, restoring its vascular function. Studies evaluating cGP, IGF-1 and IGFBP3 levels suggest that cGP concentration and cGP/IGF-1 molar ratio were positively associated suggesting that older people with higher plasma cGP concentration (and cGP/IGF-1 molar ratio) have better memory/cognitive retention.
Growth hormone-releasing peptide 6 (GHRP-6) (developmental code name SKF-110679), also known as growth hormone-releasing hexapeptide, is one of several synthetic met-enkephalin analogues that include unnatural D-amino acids, were developed for their growth hormone-releasing activity and are called growth hormone secretagogues. They lack opioid activity but are potent stimulators of growth hormone (GH) release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor. This receptor was originally called the growth hormone secretagogue receptor (GHSR), but due to subsequent discoveries, the hormone ghrelin is now considered the receptor's natural endogenous ligand, and it has been renamed as the ghrelin receptor. Therefore, these GHSR agonists act as synthetic ghrelin mimetics. It has been discovered that when GHRP-6 and insulin are administered simultaneously, GH response to GHRP-6 is increased (1). However, the consumption of carbohydrates and/or dietary fats, around the administration window of GH secretagogues significantly blunts the GH release. A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2). There are still many questions regarding this fairly new compound.
== Terminology == Scottish law professor James Lorimer is credited with coining the term "international organization" in an 1871 article in the Revue de Droit International et de Legislation Compare. Lorimer used the term frequently in his 2-volume Institutes of the Law of Nations (1883, 1884). Other early uses of the term were by law professor Walther Schucking in works published in 1907, 1908 and 1909, and by political science professor Paul S. Reinsch in 1911. In 1935, Pitman B. Potter defined international organization as "an association or union of nations established or recognized by them for the purpose of realizing a common end". He distinguished between bilateral and multilateral organizations on one end and customary or conventional organizations on the other end. In his 1922 book An Introduction to the Study of International Organization, Potter argued that international organization was distinct from "international intercourse" (all relations between states), "international law" (which lacks enforcement) and world government. International Organizations are sometimes referred to as intergovernmental organizations (IGOs), to clarify the distinction from international non-governmental organizations (INGOs), which are non-governmental organizations (NGOs) that operate internationally. These include international nonprofit organizations such as the World Organization of the Scout Movement, International Committee of the Red Cross (ICRC), and Médecins Sans Frontières, as well as lobby groups that represent the interests of multinational corporations.
Sources: en.wikipedia.org
== Size of listings == The size of the darknet markets economy can be problematic to estimate. A study based on a combination of listing scrapes and feedback to estimate sales volume by researchers at Carnegie Mellon University captured some of the best data. A reviewed 2013 analysis put the Silk Road grossing $300,000 a day, extrapolating to over $100 million over a year. Subsequent data from later markets has significant gaps as well as complexities associated with analysing multiple marketplaces.
== Bibliography == Catinon, M., Ayrault, S., Boudouma, O., Bordier, L., Agnello, G., Reynaud, S., & Tissut, M. (2014). Isolation of technogenic magnetic particles. Science of the Total Environment, 475, 39-47 (abstract).
=== Increased risk of depression === It has been claimed that insomnia causes depression and hypothesized that insomnia medications may help to treat depression. However, an analysis of data of clinical trials submitted to the Food and Drug Administration (FDA) concerning the drugs zolpidem, zaleplon, and eszopiclone found that these sedative hypnotic drugs more than doubled the risks of developing depression compared to those taking placebo pills. Hypnotic drugs, therefore, may be contraindicated in patients with or at risk of depression. Hypnotics were found to be more likely to cause depression than to help it. Studies have found that long-term users of sedative hypnotic drugs have a markedly raised suicide risk as well as an overall increased mortality risk. Cognitive-behavioral therapy (CBT) for insomnia, on the other hand, has been found to both improve sleep quality as well as general mental health.
Sources: en.wikipedia.org
== Advertising == Sonic ran its first television advertisement in 1977. One of the company's most memorable advertising campaigns, which ran from 1987 to 1993, featured Frankie Avalon. In May 1999, the company began a new campaign featuring the character Katie the Carhop. Sonic was also involved with NASCAR. The company contracted with Richard Childress Racing in late 2000 to be an associate sponsor for Dale Earnhardt Sr. during the 2001 NASCAR Winston Cup Series season. After Earnhardt died in an accident at the 2001 Daytona 500, the company continued its sponsorship with his replacement driver Kevin Harvick, through the end of the 2003 season. Sonic returned to NASCAR several years later to sponsor Sam Hornish Jr. and Richard Petty Motorsports in 2015. In 2004, the company became more widely known nationally by advertising in television markets hundreds of miles from its nearest franchise. Improvisational actors T. J. Jagodowski and Peter Grosz became known to American television viewers from their "Two Guys" series of commercials. Similar series of ads for the company have featured other duos of improvisational performers, including Molly Erdman and Brian Huskey, Katie Rich and Sayjal Joshi, and Emily Wilson and Tim Baltz. In 2010, national auditions were held and a new series of commercials began airing, some of which featured carhops from Wisconsin and Austin, Texas. In 2012 the "Two Guys" returned to the company's television ads. In 2018 Sonic supplemented their "Two Guys" commercials with complementary "Two Gals" commercials.
Seven Hezbollah members were killed during the clashes. The IDF shelled Meiss Ej Jabal Hospital, injuring a doctor. Lebanon's Ministry of Public Health condemned the attack, saying that "Israeli authorities were fully responsible for this unjustifiable act, which would have led to catastrophic results", and called for an investigation. The Amal Movement, an ally of Hezbollah, announced that a fighter was killed in a missile attack in the village of Rab El Thalathine which also wounded two other members on 11 November. These were the first casualties from the group since it joined the fighting. On 12 November, Hezbollah anti-tank missile and mortar attacks killed an employee of the Israel Electric Corporation who was conducting repair work and injured 21 other Israelis, including seven IDF members and six of the fatality's colleagues. Hezbollah also struck an IDF bulldozer in a separate attack. The IDF said it had launched a drone strike at a militant cell that tried to launch antitank missiles near Metula. Further clashes also killed one Hezbollah member. Following a Hezbollah strike on 13 November, the IDF responded with heavy shelling across southern Lebanon which reportedly killed two people, according to a first-responder organisation affiliated to the Hezbollah-allied Amal Movement. Unidentified fighters fired anti-tank guided missiles that injured two Israelis near Netu'a. An Israeli rocket struck near journalists in Yaroun, Lebanon, no casualties were reported. Hezbollah condemned the attack, which happened while the journalists were on a public tour in the town.
This method has been described as the most viable means of disposing of radioactive waste, and as the state-of-the-art as of 2001 in nuclear waste disposal technology. Another approach termed Remix & Return would blend high-level waste with uranium mine and mill tailings down to the level of the original radioactivity of the uranium ore, then replace it in inactive uranium mines. This approach has the merits of providing jobs for miners who would double as disposal staff, and of facilitating a cradle-to-grave cycle for radioactive materials, but would be inappropriate for spent reactor fuel in the absence of reprocessing, due to the presence of highly toxic radioactive elements such as plutonium within it. Deep borehole disposal is the concept of disposing of high-level radioactive waste from nuclear reactors in extremely deep boreholes. Deep borehole disposal seeks to place the waste as much as 5 kilometres (3.1 mi) beneath the surface of the Earth and relies primarily on the immense natural geological barrier to confine the waste safely and permanently so that it should never pose a threat to the environment. The Earth's crust contains 120 trillion tons of thorium and 40 trillion tons of uranium (primarily at relatively trace concentrations of parts per million each adding up over the crust's 3 × 1019 ton mass), among other natural radioisotopes.
== History == Desomorphine was first discovered and patented in Germany by a German team working for Knoll in 1920. Desomorphine was later synthesised in the U.S. in 1932 and patented on 13 November 1934. In Russia, desomorphine was declared an illegal narcotic analgesic in 1998. However, while codeine-containing drugs generally have been prescription products in Europe, in Russia they were sold freely over the counter until June 2012. The number of users in Russia was estimated to have reached around one million at the peak of the drug's popularity.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.